Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Local delivery of smooth muscle cell targeted aptamer to inhibit neointimal growth and accelerate vascular healing

Award Number: R01EB028798
ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2020
PERIOD OF PERFORMANCE END DATE: 03/31/2025

Group Awards By:

View Award Description

Local delivery of smooth muscle cell targeted aptamer to inhibit neointimal growth and accelerate vascular healing - Project Summary Interventional strategies to treat patients with obstructive peripheral artery disease (PAD), which affects 8.5 million adults in the US, are failing due to high rates of restenosis. A vital process in restenosis is the activation of vascular smooth muscle cells (VSMCs), resulting in their migration and proliferation into the intimal layer, re- occluding the artery. In the peripheral vasculature, the majority of stents fracture (up to 68%) due to excessive arterial deformation, resulting in restenosis at the fracture sites and disrupting drug release kinetics. In these cases, balloon angioplasty is often the only treatment option, however, outcomes are inferior to stents. To overcome the limitations of stents and balloon angioplasty in the treatment of PAD, drug coated balloons (DCBs) have emerged as an alternative approach. DCBs deliver drugs locally onto the arterial wall without the need of a metallic permanent stent platform. To date, DCBs have shown acute success but have failed to show long- term therapeutic benefit. Mechanistically though, DCBs have similar limitations to DES in that they deposit non- specific anti-proliferative drugs on the intimal surface, thereby adversely targeting endothelial cells and delaying re-endothelialization. Additionally, anti-proliferative drugs delivered by DCBs can produce downstream emboli, increasing amputation risks. Herein, we propose to develop a new strategy that delivers smooth muscle cell targeted therapy directly to the medial layer. Our preliminary results demonstrate successful delivery of VSMC- specific RNA aptamers directly to the arterial medial layer via a novel perfusion catheter. We confirm that this novel approach inhibits neointimal growth and accelerates re-endothelialization in a clinically relevant pre-clinical model. Overall, this proposal will test the hypothesis that RNA aptamer delivered by a perfusion catheter directly into the medial layer will inhibit neointimal growth and accelerate re-endothelialization during the vascular healing process. Varying conditions to maximize RNA delivery and retention using the perfusion catheter, determining VSMC proliferation and re-endothelization and identifying mechanism(s) of aptamer-medial inhibition of VSMC growth will be explored (Specific Aim 1). These studies will be accomplished using a novel ex vivo porcine artery circulatory system that mimics peripheral artery deformation. We will then quantify RNA retention, vessel remodeling and re-endothelialization in a porcine injury model (Specific Aim 2). Finally, we will evaluate the vascular response and healing of the treated RNA arteries in a diseased porcine in vivo model (Specific Aim 3). Through these aims, we will generate a targeted therapy that inhibits neointimal growth and promotes vascular healing. This innovative break-through will redefine the success of interventional therapy in the treatment of PAD.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$649 )
2025	2023	WAKE FOREST UNIVERSITY	1834 WAKE FOREST RD	WINSTON SALEM	NC	27109	FORSYTH	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	4	8/5/2025	NON-COMPETING CONTINUATION	-$649
														Subtotal = -$649

Issue Date FY: 2023 ( Subtotal = $386,338 )
2023	2023	WAKE FOREST UNIVERSITY	1834 WAKE FOREST RD	WINSTON SALEM	NC	27109	FORSYTH	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	4	3/13/2023	NON-COMPETING CONTINUATION	$386,338
														Subtotal = $386,338

Issue Date FY: 2022 ( Subtotal = $448,902 )
2022	2022	WAKE FOREST UNIVERSITY	1834 WAKE FOREST RD	WINSTON SALEM	NC	27109	FORSYTH	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	3	4/12/2022	NON-COMPETING CONTINUATION	$448,902
														Subtotal = $448,902

Issue Date FY: 2021 ( Subtotal = $517,916 )
2021	2021	WAKE FOREST UNIVERSITY	1834 WAKE FOREST RD	WINSTON SALEM	NC	27109	FORSYTH	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	2	5/29/2021	NON-COMPETING CONTINUATION	$0
2021	2021	WAKE FOREST UNIVERSITY	1834 WAKE FOREST RD	WINSTON SALEM	NC	27109	FORSYTH	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	2	4/1/2021	NON-COMPETING CONTINUATION	$517,916
														Subtotal = $517,916

Issue Date FY: 2020 ( Subtotal = $557,861 )
2020	2020	WAKE FOREST UNIVERSITY	1834 WAKE FOREST RD	WINSTON SALEM	NC	27109	FORSYTH	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	1	6/10/2020	NEW	$557,861
														Subtotal = $557,861

Grand Total All Awards = $1,910,368

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Local delivery of smooth muscle cell targeted aptamer to inhibit neointimal growth and accelerate vascular healing

Award Number: R01EB028798

ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2020

PERIOD OF PERFORMANCE END DATE: 03/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer